Gcc Biotech (India) Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 30-07-2024
- Paid Up Capital ₹ 7.07 Cr
as on 30-07-2024
- Company Age 18 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.00 Cr
as on 30-07-2024
- Revenue -50.29%
(FY 2023)
- Profit -114.14%
(FY 2023)
- Ebitda -53.97%
(FY 2023)
- Net Worth -2.96%
(FY 2023)
- Total Assets -29.20%
(FY 2023)
About Gcc Biotech (India)
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 7.07 Cr.
The company currently has active open charges totaling ₹5.00 Cr.
Anjana Majumdar and Raja Majumdar serve as directors at the Company.
- CIN/LLPIN
U85121DL2006PTC151727
- Company No.
151727
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Aug 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
- Apps
What products or services does Gcc Biotech (India) Private Limited. offer?
Gcc Biotech (India) Private Limited. offers a wide range of products and services, including Chemical Reagents & Catalysts, Chemical Test Kits, Medical Laboratory Instruments, Corona Test Kit, Industrial Chemicals & Supplies, Disinfectant Chemicals, PCR Machine.
Who are the key members and board of directors at Gcc Biotech (India)?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anjana Majumdar  | Director | 07-Aug-2006 | Current |
| Raja Majumdar | Director | 07-Aug-2006 | Current |
Financial Performance and Corporate Structure Insights of Gcc Biotech (India).
Gcc Biotech (India) Private Limited., for the financial year ended 2023, experienced significant reduction in revenue, with a 50.29% decrease. The company also saw a substantial fall in profitability, with a 114.14% decrease in profit. The company's net worth dipped by a decrease of 2.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gcc Biotech (India)?
In 2023, Gcc Biotech (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 07 Jul 2009 | ₹5.00 Cr | Open |
How Many Employees Work at Gcc Biotech (India)?
Gcc Biotech (India) has a workforce of 50 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gcc Biotech (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gcc Biotech (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
